News and Insights from the world of BranchLab.
As the regulatory landscape tightens around data privacy, many healthcare advertisers are forced to react, limiting functionality, scaling back targeting, or navigating consent challenges. BranchLab took a different path. From…
As economic and regulatory uncertainty loom over the 2025 TV upfronts, pharma marketers are rethinking how they show up across media. In Sam Bradley’s latest piece for Digiday, our EVP…
by Josh Walsh, Co-Founder & CEO, BranchLab A recent Harvard Law publication warns that Washington’s My Health My Data Act (WMHMD) could disrupt widely used advertising techniques. It’s right. And…
As regulations tighten, cleanroom technology offers a sustainable, compliant path forward for health advertising. The advertising technology ecosystem is at a crossroads. Eighty percent of consumers are concerned and confused…
BranchLab CEO, Josh Walsh, weighs in on the role state regulations will play for marketers, especially pharma advertisers, in the vacuum of federal regulation.
The advertising landscape is changing, especially for healthcare and pharmaceutical companies. This January, the New York Senate approved S929 – a groundbreaking data privacy law and significant step towards greater…
BranchLab’s Michael Parkes predicts: “State privacy regulations, such as Washington’s My Health My Data Act, will profoundly reshape pharmaceutical advertising by imposing strict limitations on the use of health data….
Unpacking the Pivotal Harvard Law Paper. Pharmaceutical advertising is undergoing a seismic shift, and Washington State is at the epicenter. A recent paper from Harvard Law has issued a transformative…
BranchLab’s Michael Parkes provides an overview of the emerging state regulations impacting the media strategies of pharmaceutical and healthcare brands, offering recommendations on how to navigate a new era of…
BranchLab CEO, Josh Walsh, weighs in on Meta’s move to implement stricter policies for health and wellness brands.
RFK Jr. has consistently advocated for a ban on pharmaceutical advertising, as evidenced by his discussions on prominent platforms like The Joe Rogan Experience and his social media posts, including…
Does the incoming Trump administration and RFK Jr.’s potential appointment as the head of Health and Human Services (HHS) spell the end of TV drug ads? Probably not, argues Josh Walsh, CEO…